Cystic fibrosis is a life-shortening disease characterized by the mutation of the salt transporter cystic fibrosis transmembrane conductance regulator (CFTR) protein. Elexacaftor/tezacaftor/ivacaftor treatment, which has been used since 2019, has had effects such as improving the quality of life, improving respiratory functions, and reducing the rate of pulmonary exacerbations. The real-life side effects of the drug are still emerging due to the new use of modulator therapies and their new spread around the world. There are no proven protocols regarding these side effects yet. Strategies for managing adverse drug reactions to these drugs are important to ensure that as many patients as possible benefit from them.